Navigation Links
Cardiac Patients Take NASA Super Plastic to Heart
Date:5/6/2009

WASHINGTON, May 6 /PRNewswire-USNewswire/ -- A NASA technology that was developed for an aerospace high-speed research program is now part of an implantable device for heart failure patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081007/38461LOGO)

NASA's Langley Research Center in Hampton, Va., created an advanced aerospace resin, named Langley Research Center's Soluble Imide, or LaRC-SI. It is highly flexible, resistant to chemicals, and withstands extreme hot and cold temperatures. The "super plastic" was determined to be biologically inert, making it suitable for medical use, including implantable devices.

"One of the advantages of this material is that it lends itself to a variety of diverse applications, from mechanical parts and composites to electrical insulation and adhesive bonding," said Rob Bryant, a NASA Langley senior researcher and inventor of the material.

In July 2004, NASA licensed the patented insulation technology to Medtronic Inc., a Minneapolis-based medical technology company. Medtronic Inc. incorporated the material into its Attain Ability left-heart lead, which the U.S. Food and Drug Administration recently approved.

The use of this NASA-developed material in a medical implant is the latest in a long line of medical applications that have benefited from NASA technology.

"Langley Research Center's Soluble Imide is an excellent example of how taxpayer investment in NASA materials research has resulted in a direct benefit beyond the aerospace sector by extending the quality of life through medical technology," Bryant said.

Heart failure occurs when the heart muscle is unable to pump effectively to meet the body's need for blood and oxygen. It is a chronic and progressive condition that affects more than five million Americans and more than 22 million individuals worldwide. Cardiac resynchronization therapy, or CRT, is designed to coordinate the contraction of the heart's two lower chambers and improve the heart's efficiency to increase blood flow to the body.

CRT devices, which are stopwatch-sized, are implanted into the chest and connected to the heart by leads, such as the Attain Ability left-heart lead. A lead is a special wire that delivers energy from a CRT to the heart muscle. Electrical impulses generated by CRTs resynchronize heartbeats and improve blood flow.

The NASA insulation material makes possible the compact and flexible design of Medtronic's CRT lead, one of the thinnest left-heart leads available. Placing a lead in the heart is widely recognized by physicians as the most challenging aspect of implanting CRT devices. The narrow design allows physicians to choose between different sites on the heart to deliver optimal therapy. The lead is delivered by an inner catheter, a feature that helps physicians place the lead directly in difficult-to-reach areas of the heart. Clinical studies in the U.S. and Canada showed physicians were successful in placing the Attain Ability lead 96.4 percent of the time.

The Langley Research Center's Soluble Imide was featured in Spinoff 2008 -- NASA's annual premier publication featuring successfully commercialized NASA technology. For more than 40 years, the NASA Innovative Partnerships Program has facilitated the transfer of NASA technology to the private sector, benefiting global competition and the economy. Since 1976, Spinoff has featured 40 to 50 of these commercial products annually.

In 1995, R&D Magazine selected the resin for an R&D 100 award as one of the top 100 technical innovations of the year.

NASA Television is airing a Video File demonstrating the technology. For NASA TV streaming video, downlink and scheduling information, visit:

http://www.nasa.gov/ntv

For more information about Langley Research Center's Soluble Imide, visit:

http://technologygateway.nasa.gov/Advanced_Materials.html

and

http://www.sti.nasa.gov/tto/Spinoff2008/hm_4.html


'/>"/>
SOURCE NASA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Corporate and Political PR Pro to Lead Sudden Cardiac Arrest Association
3. Family History Has Strong Effect on Cardiac Risk
4. American Heart Association Surgical Supplement Journal Report: Appropriate Hospital Discharge System Can Prevent Future Cardiac Events
5. Cardiac Science to Present at the UBS Global Life Sciences Conference
6. Cardiac Science Applauds Mass AED Training of Pittsburgh Educators
7. Guidelines help patients reduce risk of cardiac event before surgery
8. Cardiac Science Named to Deloittes Technology Fast 50 for Washington State
9. Cleveland Clinic and The Larry King Cardiac Foundation Partner to Provide Heart Surgery to Those in Need
10. Cardiac Science Releases New Cardiac Rehabilitation System
11. Cardiac Artery Trouble Boosts Family Heart Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... , ... Journal of Oral Implantology – Tooth loss is not ... health, including complications with speech, eating, and overcompensation of mouth due to the deficiency. ... As the number of tooth replacements increase, it is imperative to design an implant ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete ... has been honored by Enterprising Women magazine as one of its 2017 Enterprising ... women business owners. Winners have demonstrated that they have fast-growth businesses, mentor or ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... RawTrition now ... easy way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients ... the cellular level because the body recognizes its raw form (unlike the synthetically made ...
(Date:4/26/2017)... ... 26, 2017 , ... MYOLYN, a medical technology company dedicated ... received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two ... devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, ... cells) Phase I/II HOPE clinical trial in Duchenne announced today. , Coalition ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology: